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Abstract: Human histone deacetylase 8 is a well-recognized
target for T-cell lymphoma and particularly childhood neuro-
blastoma. PD-404,182 was shown to be a selective covalent
inhibitor of HDAC8 that forms mixed disulfides with several
cysteine residues and is also able to transform thiol groups
to thiocyanates. Moreover, HDAC8 was shown to be regulat-
ed by a redox switch based on the reversible formation of a
disulfide bond between cysteines Cys102 and Cys153. This
study on the distinct effects of PD-404,182 on HDAC8 re-
veals that this compound induces the dose-dependent for-
mation of intramolecular disulfide bridges. Therefore, the in-
hibition mechanism of HDAC8 by PD-404,182 involves both,
covalent modification of thiols as well as ligand mediated di-
sulfide formation. Moreover, this study provides a deep mo-
lecular insight into the regulation mechanism of HDAC8 in-
volving several cysteines with graduated capability to form
reversible disulfide bridges.
Introduction
Human histone deacetylase 8 (HDAC8) belongs to the histone
deacetylase family containing 11 human isoenzymes that are
subdivided into four classes. Contrary to most other isoen-
zymes, HDAC8 is not a member of multi-protein complexes,
but rather interacts with only a handful of established other
mostly cytosolic proteins.[1–11] HDAC8 is a validated target for
several types of cancer including T-cell lymphoma and child-
hood neuroblastoma.[12–18] In the effort to discover new potent
and selective non-hydroxamate inhibitors of HDAC8, we identi-
fied PD-404,182 in a medium-scaled compound screening cam-
paign.[19] Further studies on the mode of protein-inhibitor in-
teraction revealed that PD-404,182 is a covalent modifier of
HDAC8, forms mixed disulfides and transforms thiol groups
into thiocyanates.[20] In a further study we found that HDAC8 is
regulated by a redox switch involving cysteines Cys102 and
Cys153.
[21] H2O2 was shown to oxidize the protein resulting in a
disulfide bridge between these cysteines and concomitant re-
versible loss of enzyme activity.
Considering protein–inhibitor interactions, there are only
very few examples of drug-like small molecules that are able
to induce disulfide bond formation. Mathieu et al. showed that
thiram, a neurotoxic disulfide-containing dithiocarbamate com-
pound inhibits brain glycogen phosphorylase through the for-
mation of an intramolecular disulfide bond between Cys318 and
Cys326, known to be a redox-switch that prevents the allosteric
activation of the enzyme by AMP.[22, 23] The proposed mecha-
nism consists of the reaction of thiram with a cysteine thiol
leading to a mixed disulfide followed by the formation of an
intramolecular disulfide bond with a vicinal cysteine residue.
Another example describes the inactivation of an arginine
phosphatase by a seleno-compound that induces an intramo-
lecular disulfide bond between two adjacent active site cys-
teines via an unclear mechanism.[24] Moreover, Yang et al. re-
ported an example for the bile salt-induced isomerization from
intramolecular to an intermolecular disulfide bridge between
two subunits of a transmembrane transcription factor, which
directly activates the virulence cascade of Vibrio cholerae by a
host signal molecule.[25]
In this study, we show that PD-404,182 alters the activity of
HDAC8 through the formation of an intramolecular disulfide
bond between Cys102 and Cys153. Thus, PD-404,182 acts as a
molecular trigger that operates this redox switch resulting in
the inactive oxidized form of HDAC8. Moreover, PD-404,182,
unlike oxidation by H2O2, induces additional disulfide bridges
in HDAC8. The formation of a distinct disulfide bond between
Cys275 and Cys352 also has strong impact on HDAC8 activity,
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thus acting as allosteric regulative residues besides the already
known Cys102/Cys153 redox switch at the active site. These re-
sults provide strong evidence for a complex and until now un-
known redox-based regulation mechanism of HDAC8 involving
more than one disulfide bridge.
Results and Discussion
In a previous study, we identified PD-404,182 as a potent and
selective HDAC8 inhibitor.[19] By using time resolved HPLC-MS/
MS, we also explained the exact mechanism of PD-404,182 de-
composition in aqueous solution and subsequent mixed disul-
fide formation of various cysteines in HDAC8.[20] PD-404,182 de-
composes quickly into the corresponding sulfenamide, which
forms mixed disulfides with cysteine residues for example, in
HDAC8. Another adjacent cysteine can react with this inter-
mediate by forming an intramolecular disulfide bridge be-
tween the involved cysteine side chains (Figure 1). In the light
of our previous study about the redox regulation of HDAC8[21]
we questioned whether PD-404,182 is able to induce a disul-
fide bridge between Cys102 and Cys153 of HDAC8 through its
mixed disulfide and thus acts as a molecular trigger of the cor-
responding redox switch that regulates the enzyme activity of
HDAC8.
Structural and sequence alignments
HDAC8 contains ten cysteines, eight of them are in proximity
to each other and therefore able to form disulfides in general
(Figure 2). To clarify if these eight cysteines are conserved
through the other HDAC isoenzymes we made a structural
alignment of HDACs 1–8 (Figure 3). Additionally, we made se-
quence alignments including HDAC8 homologues from differ-
ent species (Figure S1). As discussed in the context of redox
regulation of HDAC8,[21] Cys102 is conserved in all class I HDACs
and Cys153 is conserved throughout all other HDACs. Also, both
cysteines are conserved in all HDAC8 homologues from differ-
ent species. This implies a fundamental role for Cys102 and
Cys153 for HDAC and particularly HDAC8 function.
Taking a glance at the crystal structure of HDAC8 (PDB-ID:
1T69) reveals three additional pairs of cysteines (Cys125/Cys131,
Cys275/Cys352 and Cys244/Cys287) in proximity (3.6–11.9 a be-
tween the corresponding sulfur atoms) potentially enabling
the formation of further disulfide bonds.
Cys125 and Cys131 are unique for HDAC8 and not present in
other human isoenzymes. Interestingly, these cysteines are
conserved in ortholog HDAC8 sequences from other species
with a slightly difference for HDAC8 from Schistosoma mansoni
(smHDAC8). The possible disulfide bond between Cys275 and
Cys352 is interesting because Cys275 is only conserved in HDACs
from class I and Cys352 is unique to HDAC8. Both cysteines are
conserved in HDAC8 homologues except for smHDAC8. The
same observation could be made for the last putative disulfide
bond. Cys287 is conserved in class I HDACs and Cys244 is unique
to HDAC8. Both are conserved in HDAC8 homologues and not
present in smHDAC8. To rationalize the reactivity of each disul-
fide pair, we calculated the pKa value and the solvent accessi-
ble surface area (SASA) of each mentioned cysteine in HDAC8
(Figure S7). A plot of pKa values against the logarithmic SASA
reveals that Cys153 has the lowest pKa value. Therefore, the di-
sulfide bond between Cys102 and Cys153 should be the most re-
active one. Cys275 and Cys352 are the most accessible cysteines
in HDAC8. We conclude that the reactivity of this disulfide
bond is mainly driven by accessibility. Cys125 and Cys131 range
between the two other disulfide bonds in terms of both, reac-
tivity and accessibility. Cys244 and Cys287 are the most buried
ones with the highest pKa value and thus lowest theoretical re-
activity. With these characteristic values it seems remarkable
that these cysteines can undergo disulfide formation. Never-
theless, there exists a crystal structure where precisely these
cysteines are interconnected by a disulfide bridge (PDB: 1VKG).
The alignments and the reactivity/accessibility calculations sug-
gest that HDAC8 consists of a unique pattern of cysteines not
found in other HDACs and therefore provides an excellent
basis for utilizing redox based regulation mechanisms to
achieve isoenzyme selectivity through targeted cysteine oxida-
tion or alkylation.
Figure 1. Mechanism of PD-404,182 induced disulfide formation.
Figure 2. Structural overview of the investigated Cysteine pairs in HDAC8
(PDB-ID: 1T64).




Electrophoretic mobility shift assays (EMSA)
In our previous study, the H2O2 dependent formation of a
single disulfide bond between Cys102 and Cys153 was demon-
strated by using a non-reductive electrophoretic mobility shift
assay (EMSA).[21] The difference in the mobility shift of the pro-
tein on a non-reductive SDS-PAGE depends predominantly on
the amino acid distance between the two covalently bound
cysteines. Thus, it should be possible to clarify if PD-404,182 is
inducing one or more disulfide bonds.
At first, the EMSA was performed with the HDAC8wt enzyme
(Figure 4 A). HDAC8 was incubated with different concentra-
tions of PD-404,182. Afterwards, an aliquot of the reaction mix-
ture was removed and conducted to an enzyme activity assay.
The rest of the reaction mixture was precipitated with tri-
chloroacetic acid (TCA), the supernatant was removed, and the
protein precipitate was resuspended in non-reducing sample
buffer with the addition of 50 mm NEM. The alkylation of the
protein is necessary to prevent nascent thiols from artificial ox-
idation with oxygen whilst the following non-reductive SDS-
PAGE. The concentration dependent inhibition of the wild type
enzyme shows a dependence between loss in enzyme activity
(left bar) and disulfide bond formation (right bar) (Figure 4 A).
The first band shift is identified as the disulfide bond between
Cys102 and Cys153 according to our previous study on the redox
switch of HDAC8.[21] Therefore, PD-404,182 is mainly regulating
the enzyme activity of HDAC8 by triggering its redox switch.
Interestingly, more disulfides occur at higher concentrations of
PD-404,182. The appearance of additional bands in the EMSA
experiment enabled the identification of three distinct oxida-
tive species of HDAC8 shifted to apparent lower molecular
weights on the gel (Figure 4 A). As mentioned before, the
amino acid distance is the key feature that determines diver-
gent migration behavior in an EMSA gel. The two additional
oxidative species are supposed to be disulfide bonds between
Cys287/Cys244 and Cys275/Cys352. The distance between Cys125
and Cys131 seems too small to expect a visible difference in an
EMSA gel without the utilization of special polymer-based
alkylation agents like poly (ethylene glycol)-maleimides as elec-
trophiles.
To confirm the hypothesis that the first disulfide bond
formed upon the addition of PD-404,182 is between Cys102 and
Cys153 further EMSA experiments were carried out with the
double mutant enzyme HDAC8C102S/C153S. In contrast to our ex-
pectations, the double mutant enzyme is not fully resistant to
PD-404,182. Surprisingly, the enzyme activity drops to about
50 % compared with the control (Figure 4 B). This behavior led
us to the assumption that HDAC8 contains at least one alloste-
ric regulating disulfide bond beyond the redox switch between
Cys102 and Cys153. To dissect this unexpected behavior, three
constructs were generated on the basis of the HDAC8C102S/C153S
vector, where in each case one additional pair of cysteines
is changed to serine, namely HDAC8C102S/C153S/C125S/C131S,
HDAC8C102S/C153S/C244S/C287S and HDAC8C102S/C153S/C275S/C352S. Interest-
ingly, the yield of recombinant protein varies dramatically be-
tween the mutant variants. The EMSA experiments with these
multiple mutant variants of HDAC8 clearly shows that the
HDAC8C102S/C153S/C275S/C352S variant retains nearly full enzyme ac-
tivity in the presence of even the highest used concentrations
of PD-404,182 (Figure 4 C). Therefore, we conclude that
the formation of a disulfide bond between Cys275 and Cys352 is
regulating the enzyme activity in an allosteric manner.
The EMSA results for the HDAC8C102S/C153S/C125S/C131S and
HDAC8C102S/C153S/C244S/C287S mutant variants are shown in Fig-
ure S8.
The enzyme activity of both mutant variants drops below
50 % residual activity at the highest concentrations of PD-
404,182. This underlines the assumption that the disulfide
bond between Cys275 and Cys352 is regulating the enzyme activ-
ity because this disulfide bond is still present in these mutants.
Figure 3. Structural alignment of HDAC1, 2, 3, 4, 6, 7 and 8. Cysteines are marked in black and disulfides in HDAC8 relate to black lines. Theoretical peptide
fragments are indicated with grey bars beneath the alignment. Numbers on the left and right edge indicates the amino acid numbers corresponding to fol-
lowing PDB IDs: HDAC1 (4BKX), HDAC2 (5IWG), HDAC3 (4A69), HDAC4 (2VQJ), HDAC6 (5W5K), HDAC7 (3C0Z), HDAC8 (1T69).




Moreover, we were able to show that the disulfide bond be-
tween Cys125 and Cys131 is not observable in the EMSA, because
the HDAC8C102S/C153S/C125S/C131S mutant variant behaves similarly
to the HDAC8C102S/C153S variant and shows two distinct shifts on
the EMSA gel, which correspond to the disulfide bonds be-
tween Cys244/Cys287 and Cys275/Cys352.
To test for reversibility of disulfide bond formation and verify
that the observed mobility shift on the EMSA gel occurs exclu-
sively throughout disulfide formation, the EMSA was per-
formed with the wild type enzyme and PD-404,182 with subse-
quent addition of 50 mm b-ME. No band shifts can be ob-
served implying that all changes on EMSA must be due to di-
sulfide formation. In addition, it was shown in our previous
study that inhibition of HDAC8 enzyme activity through PD-
404,182 is reversible after the addition of TCEP and b-ME.[20]
HPLC-MS/MS confirmation of induced disulfide bridges
To confirm the formation of the proposed regulating disulfide
bonds, we performed high-resolution HPLC-MS/MS experi-
ments. Therefore, we primarily induced the disulfide bonds in
HDAC8wt by the reaction with PD-404,182 under comparable
conditions and the same inhibitor/enzyme ratio (25-fold excess
of inhibitor) corresponding to the highest concentration in the
EMSA (Figure 4). A solvent control without inhibitor was car-
ried out simultaneously to ensure that the generated disulfides
are specific for the treatment. After treatment the reaction was
immediately stopped by TCA precipitation and guanidine de-
naturation of HDAC8wt followed by iodoacetamide alkylation.
Subsequently, samples were cleaved into peptides using tryp-
sin under non-reductive conditions to obtain treatment depen-
dent disulfide bonds. Possible disulfide shuffling during the di-
gestion process was prevented by mild buffer conditions,
10 mm ammonium bicarbonate pH 8.0, and relatively short di-
gestion times of three hours. To ensure the accuracy of the ac-
quired results, two independent replicates were made for the
treated and control samples (Figure S2). The chromatographic
separation of the digested samples already revealed distinct
differences in their composition between treated and non-
treated samples (Figure 5 A). Beside the decreasing total ion
Figure 4. Electrophoretic mobility shift assay (EMSA) showing disulfide bond
induced loss of enzyme activity. A) EMSA for the HDAC8wt,
B) HDAC8C102S/C153S, C) HDAC8C102S/C153S/C275S/C352S enzyme.
Figure 5. HPLC-MS/MS analysis of disulfide linked tryptic HDAC8 fragments.
A) HPLC chromatogram of the untreated and PD-404,182 treated HDAC8
samples. B) Mass spectra for the Cys125-S-S-Cys131@S-CAM, C) Cys125-S-S-
Cys131 + Cys102-S-S-Cys153, D) Cys244-S-S-Cys287, E) Cys275-S-S-Cys352 peptide frag-
ment.




current (TIC) of peptide fragments with alkylated cysteines and
increasing intensity of cyanylated cysteine fragments (not
shown,[20] for reference), the appearance of four distinct peaks
in the treated sample is most noticeable as highlighted in Fig-
ure 5 A. These new arising signals (5C, 5D and 5E) are not pres-
ent in the control samples or clearly enriched in the treated
samples (5B). For those signals the assigned masses match the
theoretical masses of the four proposed disulfide linked pep-
tides with an error below 2 ppm (Figure 5 B-E, Table S1). The
observed masses and isotopic distributions fit perfectly to the
expected masses of the disulfide linked tryptic peptides Cys125-
Cys131, Cys125-Cys132 + Cys102-Cys153, Cys244-Cys287 and Cys275-
Cys352. To confirm the identity of these interlinked peptides, we
acquired high resolution fragmentation spectra (Figures S3–
S6). Because of the quadrupole ion selection prior to collision
induced fragmentation only one peptide ion is observed and
fragmented at a time. Therefore, several situations should be
observable: 1) intermolecular linked tryptic peptides should
generate N- and C-terminal fragmentation patterns specific for
these two peptides, 2) disulfide linked fragment ions should
occur due to favored fragmentation of the more fragile pep-
tide bonds or 3) intramolecular linked fragments can be identi-
fied by the absence of carbamidomethyl (CAM) groups and a
distinct mass difference of two protons as a result of the con-
nected thiols. Also, the large size of such linked peptides, espe-
cially Cys125-Cys132 + Cys102-Cys153, can lead to internal fragmen-
tations. In this work, we were able to clearly identify all four
proposed disulfide bonds in HDAC8wt induced by PD-404,182
on the basis of all the above-mentioned states (Figures S3–S6,
Tables S2–5). The intramolecular and in proximity located disul-
fide bond between Cys125-Cys131 could be observed in several
fragment ions, where the thiols show the absent hydrogens
and CAM group. However, Cys102 was modified by a CAM
group in the same precursor ion. This was the only disulfide
linked species, which was also observed in the untreated con-
trol sample (Figure S3 and S4, Tables S2 and S3). Considering
that this disulfide bond is not observable in the EMSA, we hy-
pothesize that this disulfide bond is easily build even in the
absence of oxidizing agents. The other three disulfide linked
peptides were exclusively observed in the treated samples.
The precursor of Cys102-Cys153 shows a similar fragment pattern
of the Cys125-Cys131 peptide in addition to the N- and C-termi-
nal (b- and y-ion) fragments of the peptide, where Cys153 is lo-
cated. Only few Cys102-Cys153 linked fragments were identified,
likely because of the large size of those peptides. Both, the N-
and C-terminal fragmentations as well as several disulfide-
linked fragment ions were identified in the Cys244-Cys287 and
Cys275-Cys352 fragmentation spectra providing clear evidence
for their existence. Overall, these data confirm the presence of
all four disulfide linked peptides, especially Cys102-Cys153, Cys244-
Cys287 and Cys275-Cys352, after treatment with a 25-fold excess
of PD404,182.
Thermal shift assay provides insight into disulfide induced
enzyme stabilization
As proven by EMSA and HPLC-MS/MS, the interaction between
HDAC8 and PD-404,182 leads to several oxidized enzyme spe-
cies. In general, it would be expected that the formation of di-
sulfide bonds leads to protein stabilization. To elucidate the
effect on increasing concentrations of PD-404,182 on the over-
all stability of HDAC8, thermal shift assays were performed
using SYPRO orange dye on a real time PCR thermo cycler
(Figure 6). To allow for a meaningful comparison, the concen-
trations of HDAC8 and PD-404,182 were the same as in the
previous EMSA experiment (Figure 4). Considering that the
fluorescence of SYPRO orange increases upon binding to ex-
posed hydrophobic domains of the protein, the fluorescence
signal can not only be used to detect thermal unfolding, but
also changes in hydrophobic surface area due to conforma-
tional changes. Interestingly, at low concentrations of PD-
404,182, ranging from 1 mm to 7.8 mm the melting temperature
increases from 47 8C to about 51 8C. This correlates with the
first mobility shift on the EMSA, which is supposed to be the
Figure 6. Thermal shift assay of HDAC8 incubated with various concentra-
tions of PD-404,182. The black lines show the increase of SYPRO orange
fluorescence upon thermal unfolding of HDAC8. The dotted lines represent
the first derivatives of thermograms. Vertical dotted lines correspond to the
melting point of the untreated control sample.




disulfide bond between Cys102 and Cys153, as well as the alloste-
ric disulfide bond between Cys275 and Cys352 (Figure 4). The oxi-
dation of these residues results in a thermodynamically stabi-
lized and therefore favored conformation of the enzyme. At
15.6 mm of PD,404-182 a second inflection point is observed.
The melting point of the stabilized protein disappears, and a
second melting point occurs at about 40 8C. In the presence of
the two highest concentration of PD-404,182 the melting
point at elevated temperature disappears completely and only
one transition at lower temperature (40 8C) remains visible. We
conclude that very high concentrations of PD-404,182 inducing
the formation of two additional disulfide bridges destabilize
HDAC8 compared to its reduced form. The destabilization of
the enzyme in the presence of the highest inhibitor concentra-
tions correlates with a considerably elevated onset in the ther-
mogram, which is indicative for a dramatic change in the hy-
drophobic surface area and tertiary structure of the peroxi-
dized HDAC8 protein.
Conclusions
This study provides detailed insight into how PD-404,182 acts
as a molecular trigger of intermolecular disulfide bond forma-
tion within HDAC8. We identified the disulfide bond between
Cys102 and Cys153 as a main regulatory switch for enzyme activi-
ty after treatment with PD-404,182. Additionally, we were able
to identify an allosteric regulating disulfide bond between
Cys275 and Cys352, which inhibits HDAC8 activity to about 50 %
residual enzyme activity. A mutant HDAC8 variant, where those
four cysteines are mutated to serine retains enzyme activity at
the same concentration of PD-404,182. At higher concentra-
tions of PD-404,182 all proposed four disulfides are formed.
The findings were confirmed by tryptic digestion and mass an-
alytics. Additionally, we verified that the oxidation of the disul-
fide bonds between Cys102/Cys153 and Cys275/Cys352 results in a
thermodynamically stabilized protein and further oxidation re-
sults in a dramatic destabilization of the enzyme. The impact
of oxidation on the overall HDAC8 structure is still unclear and
needs further research.
Based on the knowledge gained in this study and the
unique pattern of regulative disulfide bonds in HDAC8, we
propose to develop covalent isoenzyme selective inhibitors
that target the identified pairs of cysteines. Corresponding
work is ongoing in our laboratory.
Experimental Section
Electrophoretic mobility shift assay (EMSA)
For the determination of ligand induced disulfide bond formation
2.5 mm wild type and mutant HDAC8 was treated with the indicat-
ed concentrations of PD-404,182 for 1 h at 30 8C in assay buffer
(pH 8.0, 25 mm Tris, 75 mm KCl, 0.001 % Pluronic F-68) in 50 mL re-
action volume. Afterwards 10 mL were removed and diluted 1:100
in assay buffer and stored on ice until the activity assay was per-
formed as described later. The remaining reaction mixture was
treated with 10 % TCA and protein precipitation was performed at
@20 8C for 20 min with subsequent centrifugation at 18 000 g for
10 min at 4 8C. Afterwards, the supernatant was removed and pre-
cipitate was dissolved in 30 mL alkylation buffer (pH 7.0) containing
150 mm NaCl, 20 mm NaH2PO4, 20 mm Na2HPO4, 5 mm EDTA,
50 mm NEM and 10 mL non-reducing Laemmli sample buffer (4x,
pH 6.8) containing 250 mm Tris, 8 % SDS, 40 % glycerol, 0.02 % bro-
mophenol blue for 30 min at 30 8C with subsequent heat denatura-
tion at 95 8C for 5 min. For the determination of the reversibility
against reducing agents the precipitate was dissolved in alkylation
buffer without NEM and 10 mL 4 V Laemmli sample buffer with the
addition of 200 mm DTT and conducted as listed above. Finally,
15 mL of the sample was subjected to SDS-PAGE and gels were
stained with Coomassie brilliant blue solution.
Enzyme activity assay
For the determination of disulfide bond induced changes in
enzyme activity 20 nm of the prior treated HDAC8 dilution was
mixed with 20 mm Boc-Lys(trifluoroacetyl)-AMC as substrate in a
black 96-well microtiter plate (Greiner) in assay buffer for 15 min at
30 8C. For the HDAC8C102S/C153S mutant the substrate reaction was
conducted for 1 h. After substrate conversion the reaction was
stopped by the addition of 1.7 mm SATFMK and fluorescent AMC
was released by the addition 0.4 mg mL@1 trypsin. Relative fluores-
cent units were measured in a microplate reader at 450 nm (lex =
350 nm) and normalized to the untreated control.
Sample preparation for mass spectrometry
HDAC8wt in storage buffer containing (pH 8.0, 150 mm KCl, 50 mm
Tris, 25 % glycerol, 1 mm TCEP) was buffer exchanged to 10 mm
NH4HCO3 pH 8.0 with mini GPC column (self-packed Bio Gel-P6,
Biorad) at 1020 g for 4 min. Buffer exchanged samples containing
25.5 mm HDAC8 were treated with no inhibitor and 25-fold excess
(637 mm) PD-404,182 (TOCRIS) for 1 h at 30 8C followed by protein
precipitation with 10 % TCA (see EMSA section). Precipitated pro-
tein was resuspended in 10 mm NH4HCO3 containing 5 m guanidine
and 10 mm iodoacetamide (Merck). Alkylation was performed at
22 8C for 20 min under exclusion of light followed by desalting
with mini GPC columns. Samples were tryptic digested with 5 mg
(50 ng mL@1) in 10 mm NH4HCO3 activated trypsin sequencing grade
(Promega) for 3 h at 37 8C and 550 rpm. Reaction was stopped by
addition of 1 % FA (VWR) and prior to injection centrifugated at
18 000 g for 10 min. 10 mL Supernatant was used for HPLC-MS in-
jection.
Acknowledgements
This work was supported by a fellowship of the Platform for
PhD students of the Technical University of Darmstadt. The ex-
cellent technical support of Michael Schrçder is gratefully ac-
knowledged. Open access funding enabled and organized by
Projekt DEAL.
Conflict of interest
The authors declare no conflict of interest.
Keywords: cysteine · HDAC8 · covalent inhibitors · redox
switch · sulfenamides




[1] N. Alam, L. Zimmerman, N. A. Wolfson, C. G. Joseph, C. A. Fierke, O.
Schueler-Furman, Structure 2016, 24, 458 – 468.
[2] F. Beckou[t, B. Hu, M. B. Roig, T. Sutani, M. Komata, P. Uluocak, V. L.
Katis, K. Shirahige, K. Nasmyth, Mol. cell 2010, 39, 689 – 699.
[3] M. A. Deardorff, M. Bando, R. Nakato, E. Watrin, T. Itoh, M. Minamino, K.
Saitoh, M. Komata, Y. Katou, D. Clark, K. E. Cole, E. de Baere, C. Decroos,
N. Di Donato, S. Ernst, L. J. Francey, Y. Gyftodimou, K. Hirashima, M. Hull-
ings, Y. Ishikawa, C. Jaulin, M. Kaur, T. Kiyono, P. M. Lombardi, L. Magna-
ghi-Jaulin, G. R. Mortier, N. Nozaki, M. B. Petersen, H. Seimiya, V. M. Siu,
Y. Suzuki, K. Takagaki, J. J. Wilde, P. J. Willems, C. Prigent, G. Gillessen-
Kaesbach, D. W. Christianson, F. J. Kaiser, L. G. Jackson, T. Hirota, I. D.
Krantz, K. Shirahige, Nature 2012, 489, 313 – 317.
[4] K. L. Durst, B. Lutterbach, T. Kummalue, A. D. Friedman, S. W. Hiebert,
Mol. Cell. Biol. 2003, 23, 607 – 619.
[5] J. Gao, B. Siddoway, Q. Huang, H. Xia, Biochem. Biophys. Res. Commun.
2009, 379, 1 – 5.
[6] D. E. Olson, N. D. Udeshi, N. A. Wolfson, C. A. Pitcairn, E. D. Sullivan, J. D.
Jaffe, T. Svinkina, T. Natoli, X. Lu, J. Paulk, P. McCarren, F. F. Wagner, D.
Barker, E. Howe, F. Lazzaro, J. P. Gale, Y.-L. Zhang, A. Subramanian, C. A.
Fierke, S. A. Carr, E. B. Holson, ACS Chem. Biol. 2014, 9, 2210 – 2216.
[7] Y. Qian, J. Zhang, Y.-S. Jung, X. Chen, PLoS One 2014, 9, e84015.
[8] C. Schçlz, B. T. Weinert, S. A. Wagner, P. Beli, Y. Miyake, J. Qi, L. J. Jensen,
W. Streicher, A. R. McCarthy, N. J. Westwood, S. Lain, J. Cox, P. Matthias,
M. Mann, J. E. Bradner, C. Choudhary, Nat. Biotechnol. 2015, 33, 415 –
423.
[9] T. B. Toro, T. J. Watt, Protein Sci. 2015, 24, 2020 – 2032.
[10] B. J. Wilson, A. M. Tremblay, G. Deblois, G. Sylvain-Drolet, V. GiguHre,
Mol. Endocrinol. 2010, 24, 1349 – 1358.
[11] N. A. Wolfson, C. A. Pitcairn, C. A. Fierke, Biopolymers 2013, 99, 112 – 126.
[12] I. Rettig, E. Koeneke, F. Trippel, W. C. Mueller, J. Burhenne, A. Kopp-
Schneider, J. Fabian, A. Schober, U. Fernekorn, A. von Deimling, H. E.
Deubzer, T. Milde, O. Witt, I. Oehme, Cell Death Dis. 2015, 6, e1657.
[13] S. Y. Park, J. A. Jun, K. J. Jeong, H. J. Heo, J. S. Sohn, H. Y. Lee, C. G. Park,
J. Kang, Oncol. Rep. 2011, 25, 1677 – 1681.
[14] I. Oehme, H. E. Deubzer, D. Wegener, D. Pickert, J.-P. Linke, B. Hero, A.
Kopp-Schneider, F. Westermann, S. M. Ulrich, A. von Deimling, M.
Fischer, O. Witt, Clin. Cancer Res. 2009, 15, 91 – 99.
[15] G. Niegisch, J. Knievel, A. Koch, C. Hader, U. Fischer, P. Albers, W. A.
Schulz, Urol. Oncol. 2013, 31, 1770 – 1779.
[16] G. Lopez, K. L. J. Bill, H. K. Bid, D. Braggio, D. Constantino, B. Prudner, A.
Zewdu, K. Batte, D. Lev, R. E. Pollock, PLoS One 2015, 10, e0133302.
[17] A. Chakrabarti, J. Melesina, F. R. Kolbinger, I. Oehme, J. Senger, O. Witt,
W. Sippl, M. Jung, Future Med. Chem. 2016, 8, 1609 – 1634.
[18] S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, J. J.
Buggy, Leukemia 2008, 22, 1026 – 1034.
[19] A. Kleinschek, C. Meyners, E. Digiorgio, C. Brancolini, F.-J. Meyer-Almes,
ChemMedChem 2016, 11, 2598 – 2606.
[20] M. Muth, N. J-nsch, A. Kopranovic, A. Kr-mer, N. Wçssner, M. Jung, F.
Kirschhçfer, G. Brenner-Weiss, F.-J. Meyer-Almes, General Subj. 2019,
1863, 577 – 585.
[21] N. J-nsch, C. Meyners, M. Muth, A. Kopranovic, O. Witt, I. Oehme, F.-J.
Meyer-Almes, Redox Rep. 2019, 20, 60 – 67.
[22] C. Mathieu, R. Duval, A. Cocaign, E. Petit, L.-C. Bui, I. Haddad, J. Vinh, C.
Etchebest, J.-M. Dupret, F. Rodrigues-Lima, J. Biol. Chem. 2016, 291,
23842 – 23853.
[23] C. Mathieu, L.-C. Bui, E. Petit, I. Haddad, O. Agbulut, J. Vinh, J.-M.
Dupret, F. Rodrigues-Lima, J. Biol. Chem. 2017, 292, 1603 – 1612.
[24] J. Fuhrmann, V. Subramanian, P. R. Thompson, ACS Chem. Biol. 2013, 8,
2024 – 2032.
[25] M. Yang, Z. Liu, C. Hughes, A. M. Stern, H. Wang, Z. Zhong, B. Kan, W.
Fenical, J. Zhu, Proc. Natl. Acad. Sci. USA 2013, 110, 2348 – 2353.
Manuscript received: April 8, 2020
Revised manuscript received: May 11, 2020
Accepted manuscript online: May 19, 2020
Version of record online: September 11, 2020
Chem. Eur. J. 2020, 26, 13249 – 13255 www.chemeurj.org T 2020 The Authors. Published by Wiley-VCH GmbH13255
Chemistry—A European Journal
Full Paper
doi.org/10.1002/chem.202001712
